Public-Private Roles in the Pharmaceutical Sector - Implications for Equitable Access and Rational Drug Use - Health Economics and Drugs Series, No. 005
(1997; 115 pages) [French] [Spanish] View the PDF document
Table of Contents
View the documentAuthors
View the documentAcknowledgements
View the documentAbbreviations and Acronyms
View the documentExecutive summary
Open this folder and view contents1. Public and private roles in the pharmaceutical sector
Open this folder and view contents2. Pharmaceutical markets: structure and performance
Open this folder and view contents3. Essential state responsibilities
Close this folder4. The public-private mix in drug markets: a global picture1
View the document4.1 Production
View the document4.2 National expenditure
View the document4.3 Drug distribution systems
View the document4.4 Household expenditures and sources of drugs
View the document4.5 Summary points
Open this folder and view contents5. Market mechanisms in public drug supply
Open this folder and view contents6. Promoting public health needs through the private sector
Open this folder and view contents7. Pharmaceutical production and public-private roles
Open this folder and view contents8. Capacity-building and the process of change
Open this folder and view contents9. Managing public-private roles
View the documentReferences
View the documentGlossary
View the documentBack Cover
 

4.4 Household expenditures and sources of drugs

Data on household expenditure complement those from other sources. Such data provide insights into both utilization patterns and the level of private out-of-pocket expenditure.

At the individual and household level, drugs represent the major out-of-pocket expenditure on health. A survey from Mali found that 80% of household expenditure on health was for modern drugs, 13% was for traditional medicine, 5% was for provider fees, and 2% was for transportation costs [35]. In Côte d'Ivoire and Pakistan more than 90% of household health expenditure was related to drugs [136]. Drugs or traditional products represent 62% of financial costs per treatment episode in Burkina Faso, with 17% for provider fees and 21% for transport and other living expenses incurred while seeking care [39].

Among 14 countries of Latin America and the Caribbean, drugs represented 35% of direct private expenditures on health. Figures ranged from slightly under 15% in the Cayman Islands and Uruguay to 44% in Peru, 45% in Guatemala, 46% in Colombia and 47% in El Salvador [94].

Household expenditure on drugs is closely tied to household income. In Ghana, for example, annual per capita drug expenditure varied from US$ 1.45 per person in the lowest-income households to $ 3.32 in middle-income households to $ 8.50 in the highest-income households [137].

Self-medication with privately purchased drugs often represents the most common treatment after home remedies. Household surveys indicate that drugs purchased from local drug sellers or pharmacies are used to treat approximately 53% of illness episodes in Burkina Faso (Figure 2). In an urban setting in Sri Lanka nearly 64% of the first actions taken by households in treating an illness were self-medication with western or traditional drugs (Figure 3). Studies on general and low-income populations in Kenya [97], Nepal [73], Rwanda [33], Thailand [108] and elsewhere [1,55] show similar high rates of medication with drugs acquired in the private sector. Even for potentially life-threatening illnesses such as malaria, self-medication through privately purchased drugs is common in both Africa and Asia [39,86].

Thus, at the household level as well as at national level, private purchase of drugs plays a major role in many countries, even for low-income populations.


Figure 2. Percentage distribution of household health-care-seeking behaviour, Burkina Faso [104]


Figure 3. Source of care for acute illnesses in Sri Lanka [112]

to previous section to next section
 

Last updated: May 3, 2013